S 1117
Alternative Names: Pan-IgG protease-Seismic Therapeutics; S-1117Latest Information Update: 10 Jun 2024
At a glance
- Originator Seismic Bio
- Class Enzymes; Recombinant proteins
- Mechanism of Action Immunoglobulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 13 Apr 2024 Pharmacodynamics and pharmacokinetics data from preclinical trial in Autoimmune disorders presented at the 76th Annual Meeting of the American Academy of Neurology (AAN-2024)
- 12 Apr 2024 Pharmacodynamics data from preclinical trial in Autoimmune disorders presented at the American Academy of Neurology (AAN-2024)
- 04 Dec 2023 Preclinical trials in Autoimmune disorders in USA (Parenteral)